- Home
- ARMN vs JANX Comparison
ARMN vs JANX Comparison
Compare ARMN & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMN
- JANX
- Stock Information
- Founded
- ARMN 1992
- JANX 2017
- Country
- ARMN Canada
- JANX United States
- Employees
- ARMN 3485
- JANX N/A
- Industry
- ARMN
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- ARMN
- JANX Health Care
- Exchange
- ARMN Nasdaq
- JANX Nasdaq
- Market Cap
- ARMN 2.0B
- JANX 1.4B
- IPO Year
- ARMN N/A
- JANX 2021
- Fundamental
- Price
- ARMN $9.90
- JANX $23.80
- Analyst Decision
- ARMN Strong Buy
- JANX Strong Buy
- Analyst Count
- ARMN 1
- JANX 11
- Target Price
- ARMN $17.00
- JANX $76.55
- AVG Volume (30 Days)
- ARMN 2.4M
- JANX 714.6K
- Earning Date
- ARMN 11-11-2025
- JANX 11-05-2025
- Dividend Yield
- ARMN N/A
- JANX N/A
- EPS Growth
- ARMN N/A
- JANX N/A
- EPS
- ARMN 0.02
- JANX N/A
- Revenue
- ARMN $646,783,000.00
- JANX $439,000.00
- Revenue This Year
- ARMN $49.45
- JANX N/A
- Revenue Next Year
- ARMN $11.08
- JANX $130.50
- P/E Ratio
- ARMN $383.54
- JANX N/A
- Revenue Growth
- ARMN 38.72
- JANX N/A
- 52 Week Low
- ARMN $3.29
- JANX $21.73
- 52 Week High
- ARMN $10.07
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- ARMN 65.01
- JANX 51.05
- Support Level
- ARMN $8.89
- JANX $21.73
- Resistance Level
- ARMN $10.07
- JANX $24.54
- Average True Range (ATR)
- ARMN 0.40
- JANX 1.07
- MACD
- ARMN -0.06
- JANX -0.03
- Stochastic Oscillator
- ARMN 84.60
- JANX 57.46
About ARMN Aris Mining Corporation
Aris Mining Corp is engaged in the acquisition, exploration, development, and operation of gold properties in Colombia, Guyana, and Canada. It owns and operates its Segovia Operations, Soto Norte Project and Marmato Mine in Colombia, the Toroparu Project in Guyana, and the Juby Project in Ontario, Canada. The company generates revenue from the sale of gold and silver.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.